Fortis Bank	R. Verhoef	HOLD (29 September 2009)
ING	L. Poloniecki	HOLD (29 Sep 2009)
Kempen & Co.	O. Izeboud / S. Soni	BUY (27 Oct 2009)
Needham & Company	A. Carr	BUY (13 Feb 2007)
Petercam	J. van de Bossche	BUY (29 Sep 2008)
Rabo Securities	F. Smeets	BUY (22 Oct 2009)
RBS	M. Gündogan	HOLD (17 Feb 2009)
SNS Securities	I. Zaanen	HOLD (3 Sep 2009)
Standard & Poor's	A. Jain	BUY (8 Aug 2009)
Theodoor Gilissen	T. Muller	BUY (22 Sep 2006)
Jefferies	P. Welford	BUY (12 Feb 2009)
Caris & Co	D. Moskowitz	BUY (28 Apr 2009)
UBS	G. v.Renterghem / M. Wales	Buy (5 Nov 2009)
EXANE BNP Paribas	V. Meunier / R. Zana	HOLD (22 Sep 2009)

Note: Crucell is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Crucell's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Crucell or its management. Crucell does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
	Crucell - A Star is Rising (October 14, 2005)
Note: This report has been prepared by Van Leeuwenhoeck Research based upon information provided by Crucell N.V. and publicly available sources. In addition, Van Leeuwenhoeck Research has published this report on request of Crucell and has been reimbursed for its services. www.vanleeuwenhoeck.com
	Quarterly Update (May 10, 2005)
	Quarterly Update (January 25, 2005)
	Quarterly Update (November 8, 2004)
	Quarterly Update (July 16, 2004)
	Crucell: Developing Biopharmaceuticals for Infectious Diseases

Note: This report has been prepared by Crucell N.V. (the “Company”) with the assistance of Crystal Research Associates, LLC based upon information provided by the Company. Crystal Research Associates has assimilated this content from publicly available information. In addition, Crystal Research Associates has been compensated in cash for its services.